skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Lanthanum carbonate is not associated with QT interval modification in hemodialysis patients

Original Research

(1432) Views  (572) Full article downloads

Authors: Biagio Di Iorio, Emanuele Cucciniello

Published Date June 2010 Volume 2010:2 Pages 89 - 93
DOI: http://dx.doi.org/10.2147/CPAA.S10218

Biagio Di Iorio1, Emanuele Cucciniello1

1Unità Operativa Complessa di Nefrologia, PO “A Landolfi”, ASL Avellino – Solofra (AV), Italy

Abstract: Lanthanum carbonate is an efficacious noncalcium, nonresin phosphate-binder that is being increasingly used in chronic kidney disease stage 5 (CKD-5) dialysis patients. Available evidence has indicated that QT interval changes correlate with mortality in healthy subjects and in dialysis patients. Experimental studies have suggested the possibility that lanthanum carbonate may produce prolongation of the QT interval. This is not accepted by other authors. There is no data confirming this in prospective clinical studies. The goal of this study was to verify the effect of lanthanum carbonate on the QT interval of the electrocardiogram (EKG) tracing.

Material and methods: We studied 25 hemodialyzed patients. After a six-month run-in period, with aluminum-hydroxide, lanthanum carbonate was administered at increasing doses: 500 mg twice a day for week 1; 750 mg, twice daily during week 2; 1000 mg twice daily during week 3; and 1000 mg three times daily during week 4. EKGs were recorded on patients prior to and 3 hours following each dialysis treatment. Assessments were made of differences in body weight; systolic blood pressure; diastolic blood pressure; length of PR and QRS complex; heart rate; QT; QT-c; QT-d; and axis of wave P, QRS complex and T using lanthanum carbonate at increasing doses.

Results: QT-c is before dialysis session during run-in 431 ± 20 msec with variation by -9 to + 1 msec (P = not significant [NS]) during lanthanum use; and 437 ± 25 msec after dialysis session with variation by -6 to -1 msec (P = NS) during lanthanum use. Any difference was observed during study among before and after dialysis session in QT-c (difference by 0.09 to 3.2%) (P = NS); and QT-d (difference by 8.6 to 9.1%) (P = NS).

Conclusion: Our study shows that lanthanum carbonate administration, at increasing doses, did not modify the EKG parameters. This effect is observed both in predialysis and in postdialysis recordings. Further studies are necessary with more prolonged observations.

Keywords: lanthanum carbonate, QT interval, QT dispersion, hemodialysis








Readers of this article also read:

Phosphate binding therapy in dialysis patients: focus on lanthanum carbonate
Potentials and limitations of microorganisms as renal failure biotherapeutics
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
NMDA receptors are expressed by small-cell lung cancer and are potential targets for effective treatment
Somatotropin in the treatment of growth hormone deficiency and Turner syndrome in pediatric patients: a review
Clinical outcomes of antimicrobial lock solutions used in a treatment modality: a retrospective case series analysis
A common variant in the adiponectin gene on weight loss and body composition under sibutramine therapy in obesity
Rituximab in severe skin diseases: target, disease, and dose
Renal artery stenosis in kidney transplants: assessment of the risk factors
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University